1. Home
  2. LGND vs PBLS Comparison

LGND vs PBLS Comparison

Compare LGND & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ligand Pharmaceuticals Incorporated

LGND

Ligand Pharmaceuticals Incorporated

HOLD

Current Price

$306.50

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$31.46

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LGND
PBLS
Founded
1987
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.6B
IPO Year
1997
2026

Fundamental Metrics

Financial Performance
Metric
LGND
PBLS
Price
$306.50
$31.46
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
★ $256.29
N/A
AVG Volume (30 Days)
172.3K
★ 707.2K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
★ 2886.36
N/A
EPS
★ 1.63
N/A
Revenue
★ $141,102,000.00
N/A
Revenue This Year
$1.25
N/A
Revenue Next Year
$19.41
N/A
P/E Ratio
$192.70
★ N/A
Revenue Growth
★ 29.48
N/A
52 Week Low
$175.89
$25.56
52 Week High
$326.63
$42.49

Technical Indicators

Market Signals
Indicator
LGND
PBLS
Relative Strength Index (RSI) 62.46 37.75
Support Level $286.99 $26.42
Resistance Level $322.06 $33.65
Average True Range (ATR) 9.45 3.26
MACD 3.06 -0.93
Stochastic Oscillator 77.12 14.63

Price Performance

Historical Comparison
LGND
PBLS

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: